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iftung (to Z.K.), DZHKhis study sought to test the hypothesis that inducing an autoimmune response against the cardiac sodium channel
(NaV1.5) induces arrhythmias.Background Sporadic evidence supports the concept that autoantibodies may cause cardiac arrhythmias but substantial
experimental investigations using in vivo models have been lacking to date. The NaV1.5 is essential for cardiac
impulse propagation and its dysfunction has been linked to conduction disease.Methods Rats were immunized with a peptide sequence derived from the third extracellular loop of the ﬁrst domain of
NaV1.5. After 28 days, we evaluated in vivo both the electrical and mechanical parameters of cardiac function.
Histopathology, myocardial gene and protein expression were assessed. Whole-cell patch-clamp was used to
measure sodium current (INa) density in isolated cardiomyocytes.Results NaV1.5-immunized rats had high titers of autoantibodies against NaV1.5. On ECG recording, NaV1.5-immunized
animals showed signiﬁcantly prolonged PR-intervals. During Holter ECG-monitoring we observed repeated prolonged
episodes of third-degree atrioventricular and sinoatrial block in every NaV1.5-immunized animal, but not in controls.
Immunization had no effect on cardiac function. In comparison to controls, myocardial NaV1.5 mRNA and protein
levels were decreased in immunized rats. INa density was reduced in cardiomyocytes incubated with sera from
NaV1.5-immunized rats and from patients with idiopathic atrioventricular block (AVB) in comparison to sera from
respective controls. In patients with idiopathic AVB, we observed autoantibodies against NaV1.5 that were absent in
sera from healthy controls.Conclusions Provocation of an autoimmune response against NaV1.5 induces conductance defects probably caused by a reduced
expression level and an inhibition of NaV1.5 by autoantibodies, resulting in decreased INa. (J Am Coll Cardiol
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341in the pathomechanismof dilated cardiomyopathy (2).Among
these, antibodies against beta1-adrenergic receptors and
muscarinic M2-acetylcholine receptors have been associated
with cardiac arrhythmias (3). Whereas the inﬂammatory
process may itself be arrhythmogenic, changes in the electro-
physiological properties of the myocardium also play a crucial
role. In linewith this notion, autoantibodies targeting the cardiac
KCNH2 ion channel (human ether-a-go-go–related gene) have
recently been associated with an exclusively electrophysiological
phenotype with QT prolongation in a case report (4).
Most of the currently available data rely on clinical associations
between the occurrence of distinct autoantibodies and ar-
rhythmias (5,6). Unlike for cardiomyopathy phenotypes, a
causative experimental investigation in an animal model has not
been performed to date that evaluates whether autoimmunity
against a speciﬁc cardiac target may sufﬁce to monocausally
induce an electrophysiological phenotype. However, such
evidence may be highly relevant to motivate and guide future
clinical investigations.
In cardiomyocytes, voltage-gated sodium channels are
crucial for the initiation and conduction of action potentials.
The alpha subunit of the cardiac sodium channel NaV1.5 is
encoded by the SCN5A gene and is the predominant isoform
in the heart. Heterozygous mutations in SCN5A leading to
cardiac sodium channelopathies have been associated with
a range of cardiac phenotypes including progressive cardiac
conduction defect, sick sinus syndrome, long QT syndrome
type 3, Brugada syndrome, atrial ﬁbrillation, and even
dilated cardiomyopathy (7–9). NaV1.5 is located in the
sarcolemma of cardiomyocytes and consists of four homol-
ogous domains (DI-DIV), with each domain composed of
six transmembrane segments (S1–S6) connected to each
other by alternating extracellular and cytoplasmic loops.
Hence, we studied the functional effects of antibodies
induced against the third extracellular loop of the ﬁrst
domain of the NaV1.5.
Methods
See the Online Appendix for further details.
Animals. Male Lewis rats (8 weeks old; Charles River,
Sulzfeld, Germany) were housed at 22  2C under 12-h
light/dark cycles and were fed a standard laboratory rat
diet and water ad libitum. The rats were acclimatized for at
least 1 week before experiments. All animals received
humane care in compliance with the Principles of Labora-
tory Animal Care, formulated by the National Society for
Medical Research; the Guide for the Care and Use of
Laboratory Animals, prepared by the Institute of Laboratory
Animal Resources and published by the National Institutes
of Health (publication no. 86-23, revised 1996); and the
German animal protection code. Approval was also granted
by the local ethics review board (G-135/10).
NaV1.5-peptide. The NaV1.5 peptide (GNLRHKCVRN
FTELNGTNGSVEADGLVW) corresponding to the
third extracellular loop of the NaV1.5 (residues 275–302),between the ﬁfth and sixth trans-
membrane segment of the ﬁrst
domain was synthesized and pu-
riﬁed through high-performance
liquid chromatography with a




immunization of animals. Rats
were randomly assigned to one of
two groups: the NaV1.5-peptide
immunized group (n ¼ 10) or
the control group (n ¼ 11).
Immunization (on days 0, 7, and
14) was performed through a
subcutaneous injection of 0.1 mL
of emulsion containing 500 mg
of NaV1.5 peptide dissolved in
complete Freund’s adjuvant sup-
plemented with 5 mg/mL of
Mycobacterium tuberculosisH37Ra
(Sigma, St. Louis, Missouri).
Control rats received buffer with
supplemented complete Freund’s
adjuvant. The experiment was
terminated on day 28.
Enzyme-linked immunosorbent assay for autoantibodies
detection. Serum samples were obtained after centrifuga-
tion of blood collected from rats on days 0, 7, 14, 21, and 28.
Antibody levels were determined using the enzyme-linked
immunosorbent assay technique, as described elsewhere (10).
Electrocardiography. Standard 12-lead electrocardiog-
raphy (ECG) was recorded for 1 h on days 21 and 28.
Telemetry ECG. On day 25, rats were implanted with
transmitter devices (ECG Device, Data Sciences Interna-
tional, St. Paul, Minnesota) for ECG recordings for a period
of 24 h.
In vivo hemodynamic measurements. On day 28, left
ventricular (LV) pressure–volume analysis of cardiac func-
tion was performed using a 2-Fr microtip pressure–volume
catheter (SPR-838, Millar Instruments, Houston, Texas), as
described elsewhere (11).
Histopathology. The heart was removed, and the right
atrium and atrioventricular septum were cut away from the
ventricles. The right atrium was opened by a longitudinal
incision through the tricuspid valve and into the superior
vena cava (n¼ 4–6). Additionally, 5 or 6 hearts were dissected
longitudinally into 2 symmetric sections. Formalin-ﬁxed,
parafﬁn-embedded tissues were stained with hematoxylin and
eosin (H&E) and Masson’s trichrome to determine the extent
of inﬂammation and ﬁbrosis, respectively, as described else-
where (12).
Quantitative polymerase chain reaction. Myocardial gene
expression of NaV1.5, a tissue inhibitor of metalloproteinase
(TIMP)-1 and matrix metalloproteinases (MMP)-2, -9, and -14
Table 1 General Characteristics
Characteristic
NaV1.5
(n ¼ 6 rats)
Control
(n ¼ 5 rats)
Body weight, g 305  7 305  8
Heart weight, g 0.99  0.01 0.99  0.03
Heart–to–body weight ratio ( 10–3) 3.25  0.07 3.24  0.05
Heart rate, beats/min 367  8 370  22
Systolic blood pressure, mm Hg 139  8 133  2
Diastolic blood pressure, mm Hg 109  5 109  3
Mean arterial pressure, mm Hg 119  6 117  3
Values are mean  SEM unless otherwise indicated. Na 1.5 ¼ cardiac sodium channel.
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342was performed by quantitative polymerase chain reaction.
Sample quantiﬁcations were normalized to the ribosomal
protein L32 expression.
Western Blot. Myocardial protein expression of NaV1.5
was performed by western blot using pooled serum from
NaV1.5-immunized rats or primary antibodies speciﬁc to
NaV1.5 (Abcam, Cambridge, United Kingdom).
Ventricular cardiomyocyte isolation and treatment. Adult
ventricular cardiomyocytes were isolated using methods
described elsewhere (13). After 1 h, the medium of isolated
cardiomyocytes was changed to a medium containing 1:10
diluted pooled sera from control rats or from NaV1.5-
immunized rats, or 1:2 diluted pooled sera from healthy
human controls or frompatients with idiopathic atrioventricular
block (AVB), respectively, and then incubated again for at least 1
h. Cardiomyocytes were examined only after this incubation
period. Instantaneous effects of direct application of sera were
due to the limited availability of the rat serum not investigated.
Whole-cell patch clamp recordings. The effects of pooled
sera from NaV1.5-immunized rats (n ¼ 6) on the density
of voltage-gated sodium current (INa), transient outward
potassium current (Ito) and voltage-gated L-type calcium
current, and the effects of pooled sera from patients with
idiopathic AVB (n ¼ 10) on the density of INa and Ito, were
examined using whole-cell patch clamp on isolated rat
ventricular cardiomyocytes. As negative controls, pooled sera
from control rats (n ¼ 5) or pooled sera from healthy human
controls (n ¼ 10) were used.
Screening for autoantibodies. A peptide microarray–based
screening for autoantibodies against epitopes of pre-deﬁned
168 different antigens associated with cardiovascular disease
was performed with two pooled serum samples (PEPper-
PRINT GmbH, Heidelberg, Germany). Patients from ourFigure 1 Humoral Immune Response Induced by NaV1.5 Immunizatio
(A) Time-course of anti-NaV1.5 immunoglobulin G titers measured with enzyme-linked im
conﬁrmed by western blotting using pooled serum from control and NaV1.5-immunized ra
channel.outpatient center diagnosed with idiopathic AVB in the
absence of structural heart disease were included into the ﬁrst
group (n¼ 10; clinical characteristics shown in results section).
Healthy individuals without a history of cardiovascular disease,
with normal ECG ﬁndings, with normal LV function, and
without abnormalities on cardiac magnetic resonance tomog-
raphy investigation served as the control group (n ¼ 10). All
participants gave written informed consent.
Statistical analysis. All data are expressed as mean 
SEM. The Student t test was used to analyze the differences
between the groups. A value of p < 0.05 was considered
statistically signiﬁcant.
Results
Baseline characteristics of the immunized rats and
humoral immune response induced by NaV1.5 immuni-
zation. In rats immunized with a NaV1.5-peptide, there
were no signiﬁcant differences in body weight, heart weight,
ratio of heart to body weight, heart rate, systolic blood
pressure, diastolic blood pressure, and mean arterial pressure
compared with the control group (Table 1).
Vn
munosorbent assay and (B) the reactivity of autoantibodies against NaV1.5 was
ts in ventricular myocardium. *p < 0.05 versus control. NaV1.5 ¼ cardiac sodium
Figure 2
Rats Immunized With NaV1.5 Peptide Exhibit
Prolonged PR Intervals
On 12-lead electrocardiography, PR interval was measured from the beginning of
the P wave (red vertical lines) to the beginning of the QRS complex (black vertical
lines) in control and NaV1.5-immunized rats. NaV1.5 ¼ cardiac sodium channel.
Table 2 Electrocardiographic Findings
Parameter
NaV1.5
(n ¼ 5 rats)
Control
(n ¼ 5 rats)
Heart rate, beats/min
Day 21 351  10 351  9
Day 28 333  9 338  6
PR, ms
Day 21 51  1* 45  1
Day 28 51  1* 46  1
QRS, ms 30  1 29  1
Day 21
Day 28 27  1 28  1
QT, ms 91  2* 76  2
Day 21
Day 28 85  3 79  3
nQTc,y ms 91  2* 76  2
Day 21
Day 28 85  3 79  3
ST elevation, mV 0.08  0.01 0.09  0.01
Day 21
Day 28 0.07  0.00 0.06  0.01
ValuesaremeanSEMunless otherwise indicated. *p < 0.05 versus control. ynQTc ¼ QT/(RR/f)1/2.
bpm ¼ beats per min; PR ¼ pulse rate; NaV1.5 ¼ cardiac sodium channel.
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343To study the humoral immune response following immu-
nization, total IgG autoantibody titers against NaV1.5 in
serum were measured on days 0, 7, 14, 21, and 28. Antibodies
were detectable on day 14 and displayed a high IgG response
from day 21 on. All rats immunized with NaV1.5 peptide
had higher levels of autoantibodies against NaV1.5-peptide
compared with those in the control group (Fig. 1A).Western blot analysis performed using sera from rats
immunized with NaV1.5 against ventricular myocardial
homogenates revealed a band approximating 227 kDa,
corresponding to the predicted molecular weight of NaV1.5
(Fig. 1B).
ECG alterations in animals immunized with NaV1.5. In
12-lead ECGs, rats immunized with NaV1.5-peptide showed
a signiﬁcant prolongation of PR intervals in comparison to
those in control animals (Fig. 2). This effect was observed
on days 21 and 28 at similar magnitude (51 vs. 45–46 ms;
p < 0.05). In contrast, heart rate and QRS interval were not
signiﬁcantly different between the two groups (Table 2). No
relevant ST-segment alterations or Brugada-like ECG
patterns were observed. Mean QT/QTc intervals were longer
in NaV1.5-immunized animals in comparison to those in
controls on day 21 (91 vs. 76 ms; p < 0.05). However, this
effect was attenuated on day 28 (85 vs. 79 ms), and the
resulting difference was no longer signiﬁcant.
Due to the alterations observed in the baseline 12-lead
ECG recordings, we also obtained continuous telemetric
24-h Holter ECG recordings (Fig. 3). In control animals,
we did not observe ECG signs of conduction defects. Those
animals exhibited largely stable PP and RR intervals
(Fig. 3A). Notably, we did not ﬁnd episodes of second- or
third-degree AVB or sinoatrial block in any of the control
animals. Only rarely, we observed the loss of a single
atrioventricular conduction of a P wave resulting in RR-
interval prolongation of up to a maximum of 0.5 s
(Fig. 3B). By contrast, all animals immunized with NaV1.5
peptide exhibited episodes of intermittent third-degree AVB
and sinoatrial block with RR intervals of up to 1.0 s
(Figs. 3C, 3D, 3E, and 3F). To quantify the number of
longer conduction defects, we used a cutoff value of 0.6 s
Figure 3 Cardiac Conduction Defects in Rats Immunized With NaV1.5-Peptide
Representative telemetry ECG tracings from control-rats (A1-A2 and B1-B2) and from rats immunized with NaV1.5-peptide (C1-C2, D1-D2, E1-E2, and F1-F2). Summary data of
the mean number of RR-intervals greater than 0.600 s in the 24-h ECG recordings are shown comparing immunized animals and control animals (G). NaV1.5 ¼ cardiac sodium
channel.
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344for RR intervals. We observed in rats immunized with
NaV1.5 peptide a mean of three respective episodes with RR
intervals 0.6 s during a 24-h recording and none in the
control rats (Fig. 3G).Ventricular arrhythmias such as monomorphic and poly-
morphic ventricular premature beats (Online Fig. 1) were
only rarely observed, without signiﬁcant differences between
NaV1.5-peptide–immunized rats and control rats.
Table 3 Cardiac Hemodynamic Parameters
Parameter
NaV1.5
(n ¼ 6 rats)
Control
(n ¼ 5 rats)
LV end-systolic pressure, mm Hg 129  4* 115  5
LV end-diastolic pressure, mm Hg 6.1  0.7 4.8  0.2
End-systolic volume, ml 66  11 64  25
End-diastolic volume, ml 129  11 119  32
Stroke volume, ml 63  6 56  11
dP/dtmax, mm Hg.s
1 8606  685 7036  342
dP/dtmin, mm Hg.s
1 11402  820 10932  806
Ejection fraction, % 50  5 49  6
Cardiac output, ml/min 27  3 25  4
Slope of dP/dtmax-EDV,
mm Hg $ s–1 $ ml–1
71  9 63  14
PRSW, mm Hg 83  16 62  10
Tau-g, ms 12.8  2.7 11.8  0.9
Slope of EDPVR, mm Hg $ ml–1 0.033  0.005 0.030  0.011
Values are mean  SEM. *p < 0.05 versus control.
dP/dtmax ¼maximal slope of systolic pressure increment; dP/dtmin ¼maximal slope of diastolic
pressure decrement; EDPVR ¼ end-diastolic pressure–volume relationship; EDV ¼ end-diastolic
volume; LV ¼ left ventricular; PRSW ¼ preload recruitable stroke work; Tau-g ¼ time-constant of
LV pressure decay; NaV1.5 ¼ cardiac sodium channel.
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345Effects of NaV1.5 immunization on cardiac function. Car-
diac indexes derived from pressure–volume analysis are shown
in Table 3. Immunization of rats with NaV1.5 peptide had no
effect on LV end-diastolic pressure, end-systolic volume, end-
diastolic volume, stroke volume, load-dependent (dP/dtmax)
and load-independent (slope of dP/dtmax-end-diastolic volume
and preload recruitable stroke work) contractility parameters,
ejection-phase indexes (ejection fraction and cardiac output),
indexes of the active phase of relaxation (dP/dtmin, time-
constant of left-ventricular pressure decay), or end-diastolic
stiffness (end-diastolic pressure–volume relationship). Only
LV end-systolic pressure was increased in immunized rats.
Association between NaV1.5 immunization and histo-
pathologic signs of inﬂammation or ﬁbrosis. On histo-
pathologic examination of longitudinal sections (Online Fig. 2)
and sinoatrial and atrioventricular nodes (Online Fig. 3) of
myocardial tissue, immunization with NaV1.5 peptide led to
neither inﬂammatory nor ﬁbrotic reaction, as evidenced by
H&E and Masson’s trichrome staining, respectively.
NaV1.5 immunization and down-regulation of NaV1.5
mRNA and protein expression. Quantitative polymerase
chain reaction from myocardial RNA extracts revealed that
mRNA expression for NaV1.5 was signiﬁcantly decreased
in the immunized group compared with that in the control
rats (Fig. 4A), whereas TIMP-1, MMP-2, MMP-9, and
MMP-14 mRNA levels remained unchanged (Figs. 4B, 4C,
4D, and 4E). Protein expression of NaV1.5 was also
signiﬁcantly decreased in the immunized group compared
with the control rats (Fig. 1B and Online Fig. 4).
Effects of sera from NaV1.5 immunized rats on sodium
current (INa) density in ventricular cardiomyocytes.
Figure 5A shows representative INa and Ito recordings from
ventricular cardiomyocytes. On whole-cell patch clamp
analyses, INa in cardiomyocytes incubated in medium to
which pooled sera from NaV1.5-immunized rats had beenadded was signiﬁcantly reduced compared with that in
cardiomyocytes incubated in medium to which pooled sera
from control rats had been added. Respective INa den-
sities were 4.20  0.27 picoamperes/picofarad (pA/pF) in
NaV1.5-immunized rats versus 5.95  0.37 pA/pF in
control rats (p < 0.05; n ¼ 7 rats, 17–19 myocytes)
(Fig. 5B). To evaluate the speciﬁcity of this effect for INa, we
also determined Ito density in those cardiomyocytes simul-
taneously. There was no difference in Ito after incubation
with either serum (n ¼ 7 rats, 17–19 myocytes) (Fig. 5B).
Accordingly, we did not observe a change in cardiac voltage-
gated L-type calcium channel current density in car-
diomyocytes incubated with sera from NaV1.5-immunized
rats compared with sera from the control group (n ¼ 4–5
rats, 19 myocytes) (Online Fig. 5).
Properties of pooled sera from patients with idiopathic
AVB. Pooled serum samples from patients with idiopathic
AVB in the absence of structural heart disease (Table 4) were
compared to pooled serum samples from healthy controls
(n ¼ 10 each). In a peptide microarray–based screening of
those sera, we observed autoantibodies against different
consensus motifs of the NaV1.5 (Online Table 1) that were
absent in sera from healthy controls. There were two peptide
sequences corresponding to the third extracellular loop of
the NaV1.5, between the ﬁfth and the sixth transmembrane
segment of the ﬁrst domain. One of them overlapped with
the peptide used in the present study.
Hence, we also tested functional effects in those sera. We
found that sera from the patients with idiopathic AVB signif-
icantly reduced INa density in cardiomyocytes compared with
that in sera from healthy controls (4.77 0.36 vs. 5.93 0.28
pA/pF; p< 0.05; n¼ 21–23 myocytes) but had no signiﬁcant
effect on the Ito density measured simultaneously (Fig. 5C).
Discussion
To study the effect of autoimmunity against the alpha
subunit of cardiac voltage-gated sodium channel NaV1.5
in vivo, an autoimmune response was induced in rats through
immunization with a NaV1.5-peptide. Consequently, high
levels of autoantibodies targeting the third extracellular loop
of the ﬁrst domain could be detected in blood, reﬂecting
successful immunization. Immunized animals developed an
exclusively electrical phenotype with conduction defects on
the sinoatrial and the atrioventricular level without signs of
structural heart disease or myocardial inﬂammation. On the
cellular level, this phenotype is probably caused by a reduced
density of INa in cardiomyocytes.
The NaV1.5 is composed of 4 structurally homologous
domains (DI–DIV) each consisting of 6 transmembrane
segments (S1–S6) (14). The residues between S5 and S6
form the channel pore (P loop) and control ion selectivity and
permeation. We chose a peptide sequence between S5 and
S6 within the third extracellular loop (residues 275–302) of
the ﬁrst domain for immunization because it is accessible
from the extracellular side and many single amino acid
Figure 4 Immunization of Rats With NaV1.5-Peptide Down-Regulates Myocardial NaV1.5 mRNA Expression
Quantitative PCR analysis of myocardial mRNA-levels of NaV1.5 (A), tissue inhibitor of metalloproteinase (TIMP)-1 (B), matrix metalloproteinases (MMP)-2 (C), MMP-9 (D), and
MMP-14 (E) in NaV1.5-immunized and control rats (n ¼ 5 each). *p < 0.05 versus control. NaV1.5 ¼ cardiac sodium channel.
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346mutations herein have been linked to sodium channelopathies
with different phenotypes including Brugada syndrome,
cardiac conduction defects, and sick sinus syndrome (15).
NaV1.5-immunized rats exhibited a prolonged PR
interval and intermittent third-degree AVB and sinoatrial
block with RR intervals of 0.6 to 1.0 s. Notably, intermittent
conduction blocks with RR intervals 0.6 s were observed in
every NaV1.5-immunized animal but in none of the control
animals. Rarely, we observed in control rats the loss of
a single atrioventricular conduction. Overall, these ﬁndings
are in line with a conduction defect/sick sinus syndrome
phenotype, which is clinically known from a subset of
sodium channelopathies with loss-of-function mutations inthe SCN5A gene (15). Immunized animals also exhibited
a QT/QTc-interval prolongation on day 21 that was
attenuated on day 28. In long QT syndrome type 3, which is
caused by mutations in SCN5A, phenotype variability has
been described in affected families exhibiting conduction
disease, sick sinus syndrome, and long QT syndrome (16).
Furthermore, it has been demonstrated clinically and in
transgenic models that a single structural modiﬁcation of
SCN5A by mutations may be associated with variable
phenotypes such as loss-of-function phenotypes character-
ized by conduction defects and gain-of-function phenotypes
resulting in long QT syndrome type 3 (16,17). Interestingly,
in our model of antibody-induced SCN5A interference, we
Figure 5
Sera From NaV1.5 Immunized Rats and From Patients With Idiopathic Atrioventricular Block Reduce
Voltage-Gated Sodium Current (INa) Density in Rat Ventricular Cardiomyocytes
(A) Representative recordings of INa and cardiac transient outward potassium current (Ito) in cardiomyocytes after incubation with sera from control rats (left panel) and with sera
from NaV1.5-immunized rats (right panel). (B) INa and Ito densities measured in the same cardiomyocytes for comparison after incubation with sera from controls (n ¼ 5–7 rats,
17–19 cardiomyocytes) or with sera from NaV1.5-immunized rats (n ¼ 4–7 rats, 19 cardiomyocytes). (C) INa and Ito densities in cardiomyocytes after incubation with sera from
healthy controls (n ¼ 4 rats, 23 cardiomyocytes) and with sera from patients with idiopathic atrioventricular block (n ¼ 3 rats, 21 cardiomyocytes). *p < 0.05 versus control.
pA/pF ¼ picoamperes/picofarad; NaV1.5 = cardiac sodium channel.
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347also observed an interindividual variability of electrical
phenotypes. Hence, it is plausible to speculate that the
variable QT prolongation observed in the immunized
animals may be interpreted as a consequence of autoantibody
binding and modiﬁcation of the tertiary structure of the
NaV1.5.
In whole-cell patch clamp measurements, we observed
a reduction of INa density in cardiomyocytes incubated with
sera from NaV1.5-immunized rats without a modiﬁcation of
the biophysical properties of INa. Of note, Ito in the studied
cardiomyocytes was not affected by incubation with these
sera, which is in line with a selective effect on INa. In line
with our ﬁndings, Xu et al. (18) previously generated
immunoglobulins targeting the third extracellular loop of the
ﬁrst domain for in vitro purposes and observed an inhibitory
effect of those antibodies on NaV1.5 currents in an expres-
sion system. In addition to the effects on ion currents of
antibody binding to SCN5A, there was a signiﬁcant reduc-
tion of myocardial NaV1.5 mRNA levels and protein levelsin immunized animals. This ﬁnding indicates that the
functional effects may result both from reduced expression
and inhibition of NaV1.5 in the plasma membrane by
autoantibodies, resulting in a decrease in INa. Both clinically
and in animal models, INa inhibition has been shown to
cause conduction defects and sick sinus syndrome (8,15) and
hence provides a plausible pathophysiological link between
autoimmunity and the observed phenotype.
In immunized animals, we observed PR prolongation and
intermittent third-degree AVB without prolongation of QRS
intervals. Impulse propagation through the open atrioven-
tricular node depends on L-type calcium channels, and hence
these effects may appear surprising at ﬁrst sight. Interestingly,
however, it has been described in detail that sodium channels
are localized in the pathways leading into the open node,
namely the inferior nodal extension and the transitional zone
(19). Accordingly, it has been proposed that these pathways
are the regions in which conduction defects are to be ex-
pected when sodium channel function is impaired. As the
Table 4
General and Clinical Characteristics of the Patients
With Idiopathic Atrioventricular Block (AVB)*
Age, yrs Sex Diagnosis Bundle Branch Block
91 Male AVB III No
31 Male AVB II No
71 Male AVB II (Mobitz type II) Yes (LBB)
70 Male AVB III (intermittent) Yes (alternating LBB
and RBB)
48 Female AVB II (Mobitz type II),
currently AVB III
N/A
71 Female AVB II (Mobitz type II) No
82 Male AVB II (Mobitz type II) No
73 Female AVB III No
56 Male AVB II (Mobitz type II) No
74 Male AVB III No
*In all patients, left ventricular pump function was normal, and basal rhythm ¼ sinus rhythm.
LBB ¼ left bundle branch block; RBB ¼ right bundle branch block.
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348density of sodium channels in those regions is lower than in
the working myocardium, it has been further proposed that
these regions may be particularly vulnerable to sodium
channel dysfunction caused by mutations or drugs (19). In
line with this understanding, there have been clinical reports
from patients with sodium-channel mutations that showed
conduction defects with AVB in the absence of QRS-interval
prolongation (20,21). Overall, our ﬁndings of PR prolonga-
tion and intermittent third-degree AVB without QRS
lengthening would be compatible with these observations.
Although the down-regulation of NaV1.5-expression
following immunization is a consistent ﬁnding on both
the mRNA and protein levels, the underlying intracellular
pathways are not clear. The regulation of NaV1.5 expression,
membrane targeting, and degradation is complex and has
only incompletely been elucidated to date (reviewed recently
by Rook et al. [22] and previously by Herfst et al. [23]).
Transcriptional regulation of the underlying SCN5A gene
may be modulated by intracellular signaling, by alternative
splicing, and also by alterations in cellular electrophysiology
such as altered sodium-channel gating. Functional INa
density is further modulated by anchoring proteins, signaling
pathways, and accessory subunits. To date, relatively little is
known about the mechanisms determining endocytosis and
degradation of NaV1.5. Autoantibody binding often induces
alterations of the tertiary protein structure as demonstrated
in structural analyses (24,25). Thereby, the interaction with
accessory subunits and associated proteins can be disturbed
and intracellular signaling pathways may be activated (25).
Furthermore, antibody binding has been shown to modify
degradation of membrane proteins and respective mRNA
levels (26,27). Hence, potential mechanisms could be related
to an internalization of NaV1.5 following binding of auto-
antibodies, entry of an endolysosomal degradation pathway,
and subsequent negative-feedback regulation on the level of
DNA transcription. Alternatively, other pathways may be
activated following alterations of the tertiary structure of the
channel protein, modiﬁcations of channel endocytosis, and
degradation, or as a consequence of altered cellularelectrophysiology due to direct INa reduction after autoan-
tibody binding (22–25). Additionally, in the sera from
patients with idiopathic AVB, we observed autoantibodies
binding additional peptide sequences of the NaV1.5, which
could also be examined in future research.
Study limitations. We did not assess the potential role of
the cellular immune response on immunization against
NaV1.5 but conﬁned the investigation solely to the humoral
arm of the immune system.
Conclusions
We have demonstrated for the ﬁrst time, in vivo, that
autoimmunity against an extracellular sequence motif of the
NaV1.5 induces cardiac conductance defects without signs of
structural heart disease or myocardial inﬂammation in rats.
The exclusively electrical phenotype results both from
a reduced expression level and an inhibition of NaV1.5 in the
plasma membrane by autoantibodies, causing a decrease of
INa. The ﬁndings of this study suggest a potential role
of autoimmunity against NaV1.5 in conduction defects
observed in patients without structural heart disease.
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APPENDIX
For an expanded Methods section, and a supplemental table and ﬁgures,
please see the online version of this article.
